<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124782</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210550</org_study_id>
    <nct_id>NCT05124782</nct_id>
  </id_info>
  <brief_title>Virtual Management of Rheumatoid Arthritis</brief_title>
  <acronym>ePRAT</acronym>
  <official_title>Evaluation of Rheumatoid Arthritis at the Time of Telemedicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to optimize the care of patients with RA seen in virtual&#xD;
      consultation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be organized in two consecutive steps:&#xD;
&#xD;
        1. A first descriptive step that will consist of a retrospective analysis of virtual&#xD;
           consultation records of patients with RA during the pandemic and lockdown period in&#xD;
           order to analyze on which criteria the patients were assessed and followed during this&#xD;
           period.&#xD;
&#xD;
        2. The second step will consist in evaluating the interest of the systematic use in virtual&#xD;
           consultation of a patient reported outcome (PRO), the RAID (Rheumatoid Arthritis Impact&#xD;
           of Disease) questionnaire; and analyze how its results influence the rheumatologist&#xD;
           decision-making.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of face to face consultation, hospitalization and therapeutic modifications</measure>
    <time_frame>Inclusion</time_frame>
    <description>The primary outcome will be the rate of face to face consultation, hospitalization and therapeutic modifications decided by the rheumatologist during the virtual consultation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
    <description>Patients seen in virtual consultation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rheumatoid Arthritis Impact of Disease questionnaire</intervention_name>
    <description>Rheumatoid Arthritis Impact of Disease questionnaire</description>
    <arm_group_label>Patients with rheumatoid arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis followed in a tertiary center (University Hospital&#xD;
        Cochin)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification&#xD;
             criteria&#xD;
&#xD;
          -  Follow-up in the rheumatology department of Cochin Hospital&#xD;
&#xD;
          -  Affiliated with a social security scheme&#xD;
&#xD;
          -  Non-opposition to participating in the study&#xD;
&#xD;
          -  Patients with a valid email address (registration to the virtual consultation system)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opposition to participate to this research&#xD;
&#xD;
          -  Inability to understand or speak French&#xD;
&#xD;
          -  Patient under tutor or curator ship&#xD;
&#xD;
          -  patients under medical state help&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme AVOUAC, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérôme AVOUAC, MD, PhD</last_name>
    <phone>00 33 1 58 41 25 86</phone>
    <email>jerome.avouac@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie BENHAMMANI-GODARD</last_name>
    <phone>00 33 1 58 41 11 90</phone>
    <email>marie.godard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Department, Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <state>IDF</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jérôme AVOUAC, MD, PhD</last_name>
      <phone>00 33 1 58 41 25 86</phone>
      <email>jerome.avouac@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme AVOUAC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick ALLANORE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Virtual consultation</keyword>
  <keyword>Telemedicine</keyword>
  <keyword>Patient reported outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

